EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Beyond Side Effect: Immuno-Ethical Risk Analysis of Animal-Derived Ingredients in Pharmaceuticals

Yedi Herdiana iD, Dolih Gozali, Norisca Aliza Putriana, Muchtaridi Muchtaridi iD, Shaharum Shamsuddin, Ferry Ferdiansyah Sofian iD

Risk Management and Healthcare Policy · 2026-02 · Volume 19 · 1-21

DOI: 10.2147/rmhp.s584055 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Risk Management and Healthcare Policy, 2026-02. Verfasst von Yedi Herdiana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Animal-derived ingredients (ADIs) account for up to 75% of prescription drugs, triggering clinical risks such as alpha-gal syndrome (AGS), ethical-religious conflicts, and supply transparency issues. This calls for a systematic evaluation of ADIs and accelerated development of animal-free alternatives (AFAs). This critical review synthesizes evidence from the biomedical, regulatory, and ethical literature to analyze the persistence of ADIs, map their risk stratification (biological and religious), and evaluate progress in AFAs. ADIs persist due to their functional, regulatory, and biocompatibility advantages in various medical products. Methodologically, the proposed dual risk stratification framework integrates immunological risk profiles, specifically targeting the galactose-α-1,3-galactose epitope, with Halal jurisprudential criteria for categorizing pharmaceutical ingredients. Although various AFAs (plant-based, recombinant, and synthetic) have been developed and supported by global regulatory initiatives, significant challenges in scalability, cost, and bioequivalence remain. The transition to AFAs is crucial and increasingly technically feasible. A unified framework that integrates scientific, ethical, and religious analysis is needed to accelerate the adoption of safe and inclusive AFAs, while ensuring patient autonomy and safety.

Schlagwörter

Stichwörter der Autor:innen

animal-derived ingredientsexcipient safetyhalal pharmaceuticalsimmunogenicitypharmaceutical ethicsrisk assessment

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia.
  • Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia.
  • School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
  • Nanobiotech Research Initiative, Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia.
  • Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia.

ORCID-Profile: Yedi Herdiana, Muchtaridi Muchtaridi, Ferry Ferdiansyah Sofian

Zitieren

APA

Herdiana, Y., Gozali, D., Putriana, N. A., Muchtaridi, M., Shamsuddin, S., & Sofian, F. F. (2026). Beyond Side Effect: Immuno-Ethical Risk Analysis of Animal-Derived Ingredients in Pharmaceuticals. Risk Management and Healthcare Policy, Volume 19, 1-21. https://doi.org/10.2147/rmhp.s584055

Vancouver

Herdiana Y, Gozali D, Putriana NA, Muchtaridi M, Shamsuddin S, Sofian FF. Beyond Side Effect: Immuno-Ethical Risk Analysis of Animal-Derived Ingredients in Pharmaceuticals. Risk Management and Healthcare Policy. 2026;Volume 19:1-21. doi:10.2147/rmhp.s584055

BibTeX
@article{Herdiana2026,
  author = {Herdiana, Yedi and Gozali, Dolih and Putriana, Norisca Aliza and Muchtaridi, Muchtaridi and Shamsuddin, Shaharum and Sofian, Ferry Ferdiansyah},
  title = {Beyond Side Effect: Immuno-Ethical Risk Analysis of Animal-Derived Ingredients in Pharmaceuticals},
  journal = {Risk Management and Healthcare Policy},
  year = {2026},
  volume = {Volume 19},
  pages = {1--21},
  doi = {10.2147/rmhp.s584055}
}
Kostenlos starten →